Pharmacokinetically guided Pre-dialytic Administration of Amikacin in a Haemodialysis Patient with Resistant Infections: A CARE-compliant Case Report
DOI:
https://doi.org/10.70672/rv0qnf80Keywords:
Amikacin, end-stage renal disease, therapeutic drug monitoring, pre-dialysis, case reportAbstract
Introduction: Managing carbapenem-resistant Enterobacterales (CRE) in haemodialysis patients is challenging due to the narrow therapeutic index of aminoglycosides. We report a case of a 59-year-old Malaysian male with end-stage renal disease (ESRD) and a severe CRE Klebsiella pneumoniae infection who was managed with a pharmacokinetically guided pre-dialytic amikacin strategy. Case Presentation: The patient initially failed conventional post-dialysis dosing, resulting in sub-therapeutic peaks and a toxic trough of 15 µg/mL. We switched to a pre-dialytic regimen (6–7 mg/kg), utilising high-flux dialysis as a "controlled clearance" mechanism. This achieved a bactericidal Cmax of 29.6 µg/mL, a safe trough of 9.2 µg/mL, and average AUC24 ranging from 332-399.8 mg.h/L. The patient tolerated extended pre-dialysis drug exposure of up to 10.5 hours without clinically apparent ototoxicity. However, the patient was readmitted at Day 65 with septic shock and died at Day 82; this death was not attributed to amikacin toxicity. Conclusion: This case suggests that pre-dialytic dosing may provide a safe, operationally flexible method to achieve critical pharmacokinetic/pharmacodynamic (PK/PD) targets (Cmax/MIC 8-10) in complex CRE infections, warranting further investigation in larger studies.
References
[1]. Moore H, Yeoh D, Hughes C, Raby E, Sandaradura I. Aminoglycosides: an update on indications, dosing and monitoring. Aust Prescr. 2025;48(4):133-8. https://doi.org/10.18773/austprescr.2025.038
[2]. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93-99. https://doi.org/10.1093/infdis/155.1.93
[3]. Agence française de sécurité sanitaire des produits de santé (Afssaps). Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Med Mal Infect. 2012;42(7):301-308. https://doi.org/10.1016/j.medmal.2011.07.007
[4]. Christchurch Medicines Information Service [Internet]. Christchurch (NZ): Canterbury District Health Board; 2022 May. Therapeutic drug monitoring of aminoglycosides; [cited 2026 Jul 1]. Available from: https://medicinesinformation.co.nz/bulletins/therapeutic-drug-monitoring-of-aminoglycosides/
[5]. Barclay ML, Kirkpatrick CMJ, Begg EJ. Once Daily Aminoglycoside Therapy: Is It Less Toxic Than Multiple Daily Doses and How Should It Be Monitored? Clin Pharmacokinet. 1999;36(2):89–98. https://doi.org/10.2165/00003088-199936020-00001
[6]. O’Shea S, Duffull S, Johnson DW. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? Semin Dial. 2009 May-Jun;22(3):225-30. https://doi.org/10.1111/j.1525-139X.2008.00554.x
[7]. Vossen MG, Thalhammer F. Pre-dialytic administration of aminoglycosides - case report and review of literature. GMS Infect Dis. 2013;1:Doc08. https://doi.org/10.3205/id000008
[8]. Eschenauer GA, Lam SW, Mueller BA. Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. Semin Dial. 2016 May;29(3):204-13. https://doi.org/10.1111/sdi.12458
[9]. Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother. 2021;27(1):154–60. https://doi.org/10.1016/j.jiac.2020.09.033
[10]. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007. https://www.r2library.com/Resource/Title/1930513763
[11]. Stanford Health Care Antimicrobial Safety & Sustainability Program. Stanford Health Care aminoglycoside dosing guideline [Internet]. Stanford (CA): Stanford Health Care; 2021 Jun [cited 2026 Jul 1]. Available from: https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-Aminoglycoside-Dosing-Guide.pdf
[12]. Hughes S, Heard KL, Mughal N, Moore LSP. Optimization of antimicrobial dosing in patients with acute kidney injury: a single-centre observational study. JAC Antimicrob Resist. 2022;4(4):dlac080. https://doi.org/10.1093/jacamr/dlac080
[13]. Kwee F, Andany N, Perl J, Leung E. Pharmacokinetics of Intravenous Amikacin in Intermittent Hemodialysis: Treatment of Peritoneal Dialysis Peritonitis Caused by Nontuberculous Mycobacterium (NTM). Open Forum Infect Dis. 2016 Dec;3(suppl_1):1987. https://doi.org/10.1093/ofid/ofw172.1535
[14]. Teigen MMB, Duffull S, Dang L, Johnson DW. Dosing of Gentamicin in Patients With End-Stage Renal Disease Receiving Hemodialysis. J Clin Pharmacol. 2006;46(11):1259-67. https://doi.org/10.1177/0091270006292987
[15]. Nassar L, Kurnik D, Holford N. Pharmacokinetics During Hemodialysis and Hemodiafiltration: Dialysis Clearance is more important than Dialysis Efficiency. Application to Amikacin. Presented at the PAGE 32 Abstracts of the Annual Meeting of the Population Approach Group in Europe; 2024; Abstract 10914. https://www.page-meeting.org/Abstracts/pharmacokinetics-during-hemodialysis-and-hemodiafiltration-dialysis-clearance-is-more-important-than-dialysis-efficiency-application-to-amikacin/
[16]. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA. Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended Dosing. Clin J Am Soc Nephrol. 2008;3(2):355-61. https://doi.org/10.2215/CJN.02920707
[17]. Ministry of Health, Malaysia. National Antimicrobial Guideline (NAG): Appendix 1: Clinical Pharmacokinetic Guide (Aminoglycoside, Vancomycin). National Antimicrobial Guideline (NAG). 2024 [cited 2025 Oct 23]. Available from: https://sites.google.com/moh.gov.my/nag/appendices/appendix-1-clinical-pharmacokinetic-guide-aminoglycoside-vancomycin#h.nt6jwgw2lu1h.
[18]. Sader HS, Mendes RE, Kimbrough JH, Kantro V, Castanheira M. Impact of the recent Clinical and Laboratory Standards Institute breakpoint changes on the antimicrobial spectrum of aminoglycosides and the activity of plazomicin against multidrug-resistant and carbapenem-resistant Enterobacterales from United States medical centers. Open Forum Infect Dis. 2023;10(2):ofad058. https://doi.org/10.1093/ofid/ofad058
[19]. Wicha SG. TDMx for Amikacin [software]. Version: 0.95.5 beta. 2017. doi: 10.1016/j.ijantimicag.2014.12.010.
[20]. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187-212. https://doi.org/10.1093/cid/ciac267
[21]. Nayak-Rao S. Aminoglycoside use in renal failure. Indian J Nephrol. 2010;20(3):121-126. https://doi.org/10.4103/0971-4065.70839
[22]. Cimino C, Burnett Y, Vyas N, Norris AH. Post-dialysis parenteral antimicrobial therapy in patients receiving intermittent high-flux hemodialysis. Drugs. 2021;81(5):555-574. https://doi.org/10.1007/s40265-021-01469-2
[23]. Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. New York, NY: McGraw-Hill Education; 2014. Chapter 6: Drug Dosing in Renal Disease and Hemodialysis.
[24]. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39(6):605-609. https://doi.org/10.1111/j.1365-2125.1995.tb05719.x
[25]. Osterkamp LK. Current perspective on assessment of human body proportions of relevance to amputees. J Am Diet Assoc. 1995;95(2):215-218. https://doi.org/10.1016/S0002-8223(95)00052-8
[26]. Boidin C, Bourguignon L, Cohen S, Roger C, Lefrant J-Y, Roberts JA, et al. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. Antimicrob Agents Chemother. 2019;63(11):e00993-19. https://doi.org/10.1128/AAC.00993-19.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Asian Journal of Medicine & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Engineering Technology (JET) is an open-access journal that follows the Creative Commons Attribution-Non-commercial 4.0 International License (CC BY-NC 4.0)
